CHOC Children's
Orange, California, 92868, United States
Location status: Recruiting
NCT Number: NCT04978571
The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms.
An additional purpose of this study is to demonstrate that PENFS improves functioning in children with post Covid-19 symptoms.
Interested in participating?
Request Info11 year–18 year
All sexes
Interventional
Not applicable
Orange, California, 92868, United States
Location status: Recruiting
The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms. Patient will be offered a Neurostim device. This device is placed on the outer ear through tiny needles. Since this is a randomized trial, patients may receive an active (experiment) or nonactive (control) Neurostim device. However, the nonactive control Neurostim device group will be given the option to receive an active device after the initial study procedures. The experiment group may be in this study up to 8 weeks and the control group may be in this study up to 12 weeks. The control group will have 4 additional weeks due to the transition to an active device following the first 8 weeks. The device is worn weekly for 4 weeks. Each device is worn for 5 consecutive days for the full 24 hours. The participant will be able to easily take the device off on the 6th day. Study procedures include: Neurological testing- a balance test and computerized neurological standard testing, Cardiology testing- electrocardiogram for heart rate variability (heart electrical pulse test), a pupilometer (eye) test, and parent/child questionnaires. You may benefit from this research, but there is no guarantee that being in this study will help you.
Patients in the COVID arm will be offered 6 placements of Neurostim devices. This device is placed on the outer ear through tiny needles. Patients in this arm will not be randomized, all patients will receive active devices. This group will be in the study for up to 10 weeks. The device is worn weekly for 6 weeks. Each device is worn for 5 consecutive days for the full 24 hours. The patient will be able to remove the device on the 6th day. Study procedures include: Neurological testing called Cognigram to measure cognitive functioning and parent/child questionnaires. After 6 weeks of device placements, parent and child will complete a 1-week and 1-questionnaires. You may benefit from this research, but there is no guarantee that being in this study will help you.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Concussion:
Inclusion criteria
Exclusion criteria
COVID:
Inclusion criteria
You cannot participate in this study if you meet the following exclusion criteria:
A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
Time frame: 8 weeks
With the Immediate Post-Concussion Assessment, percentiles indicate functioning assessment after a concussion. Having a higher score on this assessment implies having a worse outcome assessment.
Time frame: 8 weeks
Post Concussion Symptom Scale- a 22 item questionnaire, rated on a 0-6 scale. Having a higher score indicates having worse symptom assessment.
Time frame: 8 weeks
Balance Error Scoring Symptom- a balance test conducted in person. Patient is asked to do a 3 poses on the floor and 3 poses standing on a foam and asked to stand still. The amount of errors will be counted for the times the patient moves. The higher the errors, means patient does not have a well-balance.
Time frame: 10 weeks
COGNIGRAM is a test prescribed by clinicians to measure cognitive function.
Time frame: 8 weeks
4 item to rate abdominal pain. Higher score indicates having worse outcome.
Time frame: 8 weeks
rate on a 1-10 scale level of nausea. Higher score indicated feeling worse.
Time frame: 8 weeks
23 item to rate symptoms, higher score indicates worse symptoms
Time frame: 8 weeks
15 item, asking on functioning, higher score indicated worse outcome.
Time frame: 8 weeks
8 item questionnaire asking on anxiety level. Higher score indicates worse outcome.
Time frame: 8 weeks
8 item asking on depression, higher score indicated worse outcome
Time frame: 8 weeks
7-item asking on general health, lower score indicates worse outcome
Time frame: 10 weeks
40-item asking Covid related symptoms and history.
Time frame: 8 weeks
numerical number that determines blood pressure. Having a high blood pressure indicates worse outcome. Reading will be done by a provider.
Time frame: 8 weeks
Heart rate measurement- a recording of electrical signal from the heart to check for heart conditions. Reading will be done by a provider.
Time frame: 8 weeks
Pupillometry: An eye assessment to measure pupil size and reactivity, reading will be done by a provider
Contact information is provided by the study sponsor or research team.
Jamie Janchoi
CONTACT
Pari Mokhtari
CONTACT
Children's Hospital of Orange County
Other
A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04982562
Brain Concussion, Craniocerebral Trauma
Poitiers, France
View Trial DetailsNCT06073886
Anxiety, Anxiety Disorders
Westwood, Los Angeles, California, United States
View Trial DetailsNCT05785000
Brain Concussion, Brain Diseases
Copenhagen, Region of Greater Copenhagen, Denmark
View Trial DetailsNCT06376500
Brain Concussion, Craniocerebral Trauma
Hung Hom, Kowloon, Hong Kong
View Trial Details